{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:21:24Z","timestamp":1791195684352,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radioimmunotherapy with 90-yttrium-ibritumomab tiuxetan (90Y-IT) as first-line treatment in patients with follicular lymphoma (FL) demonstrated promising results with a complete remission (CR) rate of 56% and a median progression-free survival (PFS) of 26\u00a0months, when initially analyzed after a median follow-up of 30.6\u00a0months. The aim of this long-term follow-up was to investigate whether clinical benefits were maintained and new safety signals appeared. Fifty-nine patients, aged\u2009\u2265\u200950\u00a0years, with FL grade 1 to 3A in stages II to IV were treated with 90Y-IT as first-line therapy. If CR without evidence of minimal residual disease (MRD), partial response or stable disease was achieved 6\u00a0months after treatment, patients were observed without further treatment. Patients with CR but persisting MRD received consolidation therapy with rituximab. The primary endpoint was the clinical response rate. Secondary endpoints were time to progression, safety, and tolerability. After a median follow-up of 9.6\u00a0years, median PFS was 3.6\u00a0years, and 8-year PFS was 38.3%. Median overall survival (OS) was not reached during the extended follow-up, and 8-year OS amounted to 69.2%. Age 65\u00a0years and above or disease progression within 24\u00a0months of treatment were significantly associated with shorter OS. An important finding was the lack of new safety signals. In particular, no increase in secondary malignancies or transformation into aggressive lymphoma was observed compared to trials with a similar follow-up. In summary, 90Y-IT as first-line treatment demonstrates a favorable safety profile and long-term clinical activity in a substantial fraction of FL patients in need of therapy. ClinicalTrials.gov Identifier: NCT00772655.<\/jats:p>","DOI":"10.1007\/s00277-022-04781-3","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T13:02:41Z","timestamp":1644670961000},"page":"781-788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6\u00a0years"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-8581","authenticated-orcid":false,"given":"Kathrin","family":"Rieger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"De Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Lind\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lerch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Neumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Stroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Peuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pezzutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"issue":"11","key":"4781_CR1","first-page":"6701","volume":"34","author":"P Mondello","year":"2014","unstructured":"Mondello P, Steiner N, Wasle I, Pitini V, Mian M (2014) Radiotherapy for stage I\/II follicular lymphoma (FL): is it time for a re-appraisal? Anticancer Res 34(11):6701\u20136704","journal-title":"Anticancer Res"},{"issue":"3","key":"4781_CR2","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E et al (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 15(3):1110\u20137","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"4781_CR3","doi-asserted-by":"publisher","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Ghielmini M, Rule S et al (2016) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v83\u2013v90","journal-title":"Ann Oncol"},{"issue":"28","key":"4781_CR4","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26(28):4579\u20134586","journal-title":"J Clin Oncol"},{"issue":"12","key":"4781_CR5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B et al (2019) First-Line Treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 37(12):984\u2013991","journal-title":"J Clin Oncol"},{"issue":"26","key":"4781_CR6","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1056\/NEJMc1714337","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Seymour JF, Hiddemann W (2017) Obinutuzumab treatment of follicular lymphoma. N Engl J Med 377(26):2605\u20132606","journal-title":"N Engl J Med"},{"issue":"9759","key":"4781_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42\u201351","journal-title":"Lancet"},{"issue":"31","key":"4781_CR8","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37(31):2815\u20132824","journal-title":"J Clin Oncol"},{"issue":"23","key":"4781_CR9","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, Barbui AM, Canales MA et al (2018) Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 36(23):2395\u20132404","journal-title":"J Clin Oncol"},{"issue":"6","key":"4781_CR10","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1097\/HS9.0000000000000160","volume":"2","author":"K Herfarth","year":"2018","unstructured":"Herfarth K, Borchmann P, Schnaidt S et al (2018) Rituximab with involved field irradiation for early-stage nodal follicular lymphoma: results of the MIR study. Hemasphere. 2(6):e160","journal-title":"Hemasphere."},{"issue":"4","key":"4781_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ijrobp.2015.12.019","volume":"94","author":"M Ruella","year":"2016","unstructured":"Ruella M, Filippi AR, Bruna R et al (2016) Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study. Int J Radiat Oncol Biol Phys 94(4):783\u2013791","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"4781_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/cam4.684","volume":"5","author":"B Casadei","year":"2016","unstructured":"Casadei B, Pellegrini C, Pulsoni A et al (2016) 90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate\/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years. Cancer Med 5(6):1093\u20131097","journal-title":"Cancer Med"},{"issue":"16","key":"4781_CR13","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","volume":"31","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser F, Radford J, Van Hoof A et al (2013) 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol. 31(16):1977\u201383","journal-title":"J Clin Oncol."},{"issue":"1","key":"4781_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3109\/10428194.2013.790544","volume":"55","author":"M Provencio","year":"2014","unstructured":"Provencio M, Cruz Mora MA, Gomez-Codina J et al (2014) Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. Leuk Lymphoma 55(1):51\u201355","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"4781_CR15","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 20(10):2453\u20132463","journal-title":"J Clin Oncol"},{"issue":"3","key":"4781_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","volume":"31","author":"CW Scholz","year":"2013","unstructured":"Scholz CW, Pinto A, Linkesch W et al (2013) (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 31(3):308\u2013313","journal-title":"J Clin Oncol"},{"issue":"4","key":"4781_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244","journal-title":"J Clin Oncol"},{"issue":"23","key":"4781_CR18","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33(23):2516\u20132522","journal-title":"J Clin Oncol"},{"issue":"8","key":"4781_CR19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM et al (2016) Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 128(8):1112\u20131120","journal-title":"Blood"},{"issue":"5","key":"4781_CR20","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/bjh.12695","volume":"164","author":"A Ibatici","year":"2014","unstructured":"Ibatici A, Pica GM, Nati S et al (2014) Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol 164(5):710\u20136","journal-title":"Br J Haematol"},{"issue":"29","key":"4781_CR21","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"Martinelli G, Schmitz SF, Utiger U et al (2010) Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol 28(29):4480\u20134484","journal-title":"J Clin Oncol"},{"issue":"9873","key":"4781_CR22","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210","journal-title":"Lancet"},{"issue":"6","key":"4781_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/bjh.17045","volume":"192","author":"AA Moccia","year":"2020","unstructured":"Moccia AA, Schar S, Hayoz S et al (2020) Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol 192(6):1031\u20131034","journal-title":"Br J Haematol"},{"issue":"7","key":"4781_CR24","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","volume":"98","author":"E Bachy","year":"2013","unstructured":"Bachy E, Houot R, Morschhauser F et al (2013) Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 98(7):1107\u20131114","journal-title":"Haematologica"},{"key":"4781_CR25","doi-asserted-by":"crossref","unstructured":"Lopez-Guillermo A, Canales MA, Dlouhy I et al (2021) A randomized phase II study comparing consolidation with a single dose of (90)Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. Leuk Lymphoma 63(1):93\u2013100","DOI":"10.1080\/10428194.2021.1971216"},{"key":"4781_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.critrevonc.2016.07.008","volume":"105","author":"D Rizzieri","year":"2016","unstructured":"Rizzieri D (2016) Zevalin(\u00ae) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol 105:5\u201317","journal-title":"Crit Rev Oncol Hematol"},{"issue":"32","key":"4781_CR27","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M et al (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 26(32):5165\u20135169","journal-title":"J Clin Oncol"},{"issue":"26","key":"4781_CR28","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS et al (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31(26):3272\u20133278","journal-title":"J Clin Oncol"},{"issue":"22","key":"4781_CR29","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","volume":"34","author":"C Sarkozy","year":"2016","unstructured":"Sarkozy C, Trneny M, Xerri L et al (2016) Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol 34(22):2575\u20132582","journal-title":"J Clin Oncol"},{"issue":"12","key":"4781_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/nbt1218-1125","volume":"36","author":"E Dolgin","year":"2018","unstructured":"Dolgin E (2018) Radioactive drugs emerge from the shadows to storm the market. Nat Biotechnol 36(12):1125\u20131127","journal-title":"Nat Biotechnol"},{"issue":"9","key":"4781_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR (2020) Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19(9):589\u2013608","journal-title":"Nat Rev Drug Discov"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04781-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04781-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04781-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T12:09:11Z","timestamp":1646914151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04781-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["4781"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04781-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,12]]},"assertion":[{"value":"2 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study (NCT00772655) was performed in line with the principles of the Declaration of Helsinki. Institutional review board approval from each center and informed consent from each patient were obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"K.R. has received honoraria from Roche, BMS, Amgen, Novartis, Janssen-Cilag, and Abbvie, and reports consultant\/advisory roles for MSD and Essex Pharma. A.V. has received honoraria from Roche, Amgen, Kite\/Gilead, Novartis, and BMS, and reports consultant\/advisory roles for Roche, Amgen, Kite\/Gilead, Novartis, and BMS. C.A.P. has received honoraria from BMS, Novartis, Daiichi-Sankyo, EUSA Pharma, and Sirtex Medical, and reports a consultant\/advisory role for EUSA Pharma. U.K. reports consultant\/advisory roles for Roche, BMS, Celgene, Novartis, Gilead, Pentixapharm, EUSA Pharma, Janssen-Cilag, AstraZeneca, Hexal, MSD, Takeda, and Amgen. C.W.S. has received honoraria from GILEAD, Janssen, Pfizer, and Roche, and reports consultant\/advisory roles for BMS, Celgene, Daiichi-Sankyo, GILEAD, Hexal, Janssen, Merck Serono, Novartis, Roche, and Takeda. The other authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Clinical data contains potentially personal information and is stored with the authors. Upon request, it can be shared in anonymized form with the editors or fellow scientists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}]}}